Protalix BioTherapeutics

Pfizer receives kosher certification for Elelyso for injection

Monday, May 19, 2014

Pfizer has announced that the Orthodox Union (OU) has granted kosher certification to ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is the first prescription medication to be certified kosher by the OU, a milestone for the brand which was approved by the FDA in May 2012. 

[Read More]

FDA issues complete response to Protalix

Tuesday, March 1, 2011

The FDA has issued a complete response letter for Protalix’s Gaucher’s disease drug taliglucerase alfa. Protalix won’t be required to conduct any additional clinical studies, but that didn’t stop its stock from plunging on the news, FierceBiotech reported.

[Read More]